Wall Street analysts expect Edwards Lifesciences Corporation (NYSE:EW) to post $862.69 million in sales for the current fiscal quarter, according to Zacks. Nine analysts have made estimates for Edwards Lifesciences’ earnings. The highest sales estimate is $877.98 million and the lowest is $844.00 million. Edwards Lifesciences posted sales of $767.70 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 12.4%. The business is expected to report its next quarterly earnings results on Wednesday, February 7th.
According to Zacks, analysts expect that Edwards Lifesciences will report full year sales of $862.69 million for the current financial year, with estimates ranging from $3.37 billion to $3.42 billion. For the next year, analysts anticipate that the company will post sales of $3.71 billion per share, with estimates ranging from $3.65 billion to $3.77 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that that provide coverage for Edwards Lifesciences.
Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($0.02). The business had revenue of $821.50 million during the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The business’s revenue was up 11.1% compared to the same quarter last year. During the same period last year, the company earned $0.68 EPS.
In other Edwards Lifesciences news, Director Schack Wesley W. Von sold 1,000 shares of the stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $104.15, for a total value of $104,150.00. Following the completion of the sale, the director now directly owns 2,622 shares in the company, valued at $273,081.30. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $100.93, for a total value of $3,320,597.00. The disclosure for this sale can be found here. Insiders have sold a total of 139,580 shares of company stock valued at $14,849,205 over the last 90 days. 2.13% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in EW. ETF Managers Group LLC purchased a new position in shares of Edwards Lifesciences in the second quarter worth about $112,000. MPS Loria Financial Planners LLC purchased a new position in shares of Edwards Lifesciences in the second quarter worth about $140,000. Captrust Financial Advisors purchased a new position in shares of Edwards Lifesciences in the second quarter worth about $149,000. Dupont Capital Management Corp purchased a new position in shares of Edwards Lifesciences in the third quarter worth about $142,000. Finally, Salem Investment Counselors Inc. raised its stake in shares of Edwards Lifesciences by 16.3% in the second quarter. Salem Investment Counselors Inc. now owns 1,419 shares of the medical research company’s stock worth $168,000 after purchasing an additional 199 shares during the last quarter. Institutional investors own 81.82% of the company’s stock.
Shares of Edwards Lifesciences (NYSE EW) traded up $0.75 during trading on Wednesday, reaching $116.32. The company’s stock had a trading volume of 243,539 shares, compared to its average volume of 1,643,286. The company has a market cap of $25,009.24, a P/E ratio of 32.74, a PEG ratio of 2.11 and a beta of 0.51. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33. Edwards Lifesciences has a 12 month low of $86.55 and a 12 month high of $121.45.
Edwards Lifesciences announced that its Board of Directors has authorized a share repurchase program on Thursday, December 7th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.
COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Expect Edwards Lifesciences Corporation (EW) Will Announce Quarterly Sales of $862.69 Million” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/12/13/zacks-analysts-expect-edwards-lifesciences-corporation-ew-will-announce-quarterly-sales-of-862-69-million.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.